Skip Navigation


Annals of Oncology Advance Access originally published online on August 9, 2008
Annals of Oncology 2008 19(10):1812-1813; doi:10.1093/annonc/mdn546
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/10/1812    most recent
mdn546v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Colloca, G.
Right arrow Articles by Venturino, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colloca, G.
Right arrow Articles by Venturino, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

About sorafenib in castration-resistant prostate cancer

The first 10% of the full text of this article appears below.

In the study design of Chi et al. [1] is declared that sorafenib would be considered of interest if three or more prostate-specific antigen (PSA) responses were observed in the 25 patients accrued. In their trial, a PSA response occurred in one patient among 28 patients treated with sorafenib; therefore, sorafenib should be considered ineffective in chemonaive castration-resistant prostate . . . [Full Text of this Article]

G. Colloca1, F. Checcaglini2,* and A. Venturino1

1 Operative Unit of Medical Oncology, Ospedale Civile, Sanremo
2 Operative Unit of Radiotherapy, Città di Castello Hospital, Città di Castello, Italy

* (E-mail: oncologia@katamail.com)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. B. Aragon-Ching and W. L. Dahut
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Ann. Onc., November 10, 2009; (2009) mdp467v1.
[Full Text] [PDF]